We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+5.7%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$7.68B
AUM Growth
+$101M
(+1.3%)
Cap. Flow
-$193M
Cap. Flow
% of AUM
-2.51%
Top 10 Holdings %
Top 10 Hldgs %
17.01%
Holding
1,082
New
298
Increased
225
Reduced
230
Closed
304
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$123M |
| 2 |
CVS Health
CVS
|
+$75.5M |
| 3 |
VMW
VMware, Inc
VMW
|
+$62.2M |
| 4 |
Coca-Cola Europacific Partners
CCEP
|
+$51.2M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$50.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
T-Mobile US
TMUS
|
+$97.3M |
| 2 |
AGN
Allergan Inc
AGN
|
+$79.1M |
| 3 |
Micron Technology
MU
|
+$67M |
| 4 |
HP
HPQ
|
+$65.4M |
| 5 |
Baxter International
BAX
|
+$55.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.38% |
| 2 | Financials | 13.7% |
| 3 | Communication Services | 11.26% |
| 4 | Technology | 9.89% |
| 5 | Industrials | 8.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SCMP
651
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
| $610K | 0.01% |
+39,219
| New | +$608K |
|
652
Pediatrix Medical
MD
$2.16B
| $587K | 0.01% |
8,100
+4,999
| +161% | +$348K |
|
|
CUDA
653
DELISTED
Barracuda Networks, Inc.
CUDA
| $577K | 0.01% |
+15,002
| New | +$555K |
|
654
Ameriprise Financial
AMP
$46.8B
| $576K | 0.01% |
4,402
-46,390
| -91% | -$6.11M |
|
|
CARB
655
DELISTED
Carbonite Inc
CARB
| $572K | 0.01% |
+40,000
| New | +$582K |
|
656
LivePerson
LPSN
$18.9M
| $570K | 0.01% |
+3,715
| New | +$628K |
|
657
Spectrum Brands
SPB
$2.04B
| $564K | 0.01% |
+6,293
| New | +$588K |
|
658
Andersons Inc
ANDE
$2.65B
| $563K | 0.01% |
+13,617
| New | +$612K |
|
|
NE
659
DELISTED
Noble Corporation
NE
| $551K | 0.01% |
38,588
| – | – |
|
660
MiMedx Group
MDXG
$626M
| $529K | 0.01% |
+50,821
| New | +$476K |
|
661
Blackstone
BX
$104B
| $528K | 0.01% |
+13,836
| New | +$500K |
|
|
SRNE
662
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $513K | 0.01% |
+44,352
| New | +$513K |
|
|
GAP
663
The Gap Inc
GAP
$6.84B
| $511K | 0.01% |
+11,800
| New | +$492K |
|
|
SHLM
664
DELISTED
Schulman (A.) Inc
SHLM
| $510K | 0.01% |
10,578
-85,343
| -89% | -$3.37M |
|
|
TMH
665
DELISTED
Team Health Holdings Inc
TMH
| $510K | 0.01% |
+8,719
| New | +$494K |
|
666
Lexicon Pharmaceuticals
LXRX
$1.02B
| $507K | 0.01% |
+76,669
| New | +$524K |
|
667
Abercrombie & Fitch
ANF
$4.17B
| $503K | 0.01% |
+22,811
| New | +$562K |
|
|
PBPB
668
DELISTED
Potbelly
PBPB
| $503K | 0.01% |
+36,748
| New | +$510K |
|
|
DRII
669
DELISTED
DIAMOND RESORTS INTL, INC
DRII
| $503K | 0.01% |
+15,040
| New | +$472K |
|
670
Textron
TXT
$16.6B
| $499K | 0.01% |
+11,263
| New | +$490K |
|
671
NextEra Energy
NEE
$187B
| $497K | 0.01% |
19,092
-67,936
| -78% | -$1.79M |
|
|
PETX
672
DELISTED
Aratana Therapeutics, Inc.
PETX
| $495K | 0.01% |
+30,897
| New | +$550K |
|
673
Freeport-McMoran
FCX
$90B
| $490K | 0.01% |
25,883
-364,254
| -93% | -$7.2M |
|
674
VF Corp
VFC
$6.68B
| $487K | 0.01% |
+6,863
| New | +$475K |
|
|
ZAYO
675
DELISTED
Zayo Group Holdings, Inc.
ZAYO
| $487K | 0.01% |
+17,400
| New | +$496K |
|
Similar funds
Marshall Wace's Q1 2015 Portfolio in Review
As of Q1 2015, Marshall Wace held 1,082 positions worth $7.68B, up 1.3% from $7.57B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Marshall Wace's Q1 2015 filing shows 298 new, 225 increased, 230 reduced and 304 closed positions. Its largest new stake was Viatris: 845,509 shares worth $50.2M. The largest sale was T-Mobile US, an estimated $97.3M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 18% a quarter earlier, followed by Financials and Communication Services.
- Marshall Wace's largest Q1 2015 buy was Viatris: 845,509 shares worth $50.2M.
- Marshall Wace added most to Allergan plc in Q1 2015, an estimated $123M increase.
- Marshall Wace's biggest Q1 2015 reduction was T-Mobile US, cutting an estimated $97.3M.
- Marshall Wace fully exited Allergan Inc in Q1 2015, selling an estimated $79.1M.
- Marshall Wace's ten largest holdings make up 17% of its $7.68B portfolio in Q1 2015.
- Marshall Wace opened 298 new positions and closed 304 in Q1 2015.
- Marshall Wace's portfolio value rose 1.3% quarter-over-quarter to $7.68B.
Based on Marshall Wace's 13F filing for Q1 2015, filed 11 May 2015.